Back to top
more

Abeona Therapeutics Inc. (ABEO)

(Real Time Quote from BATS)

$20.90 USD

20.90
1,228,199

+0.90 (4.49%)

Updated Apr 20, 2018 03:58 PM ET

Add to portfolio

4-Sell       4  

F Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump

Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

ABEO  BHVN

Zacks Equity Research

Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher

Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AXON  ABEO

Zacks Equity Research

Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?

Surging implied volatility makes Abeona Therapeutics (ABEO) stock lucrative to the option traders.

ABEO

Zacks Equity Research

Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

JNJ  ABEO  KERX

Zacks Equity Research

4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

RHHBY  NVS  GILD  AMGN  ABEO  CLSD  RETA  URGN

Zacks Equity Research

Here's Why These 3 Biotech Stocks Might Stop Rallying

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

JNJ  ABEO  KERX

Zacks Equity Research

Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher

Abeona Therapeutics (ABEO) shares rose nearly 23% in the last trading session, amid huge volumes.

ALXN  ABEO

Zacks Equity Research

Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%

Abeona Therapeutics Inc. (ABEO) moved big last session, as the company saw its shares rise over 10% on the day.

ENZ  ABEO

Zacks Equity Research

Access Pharma

Access Pharma (ACCP)is a biopharmaceutical company focused on developing a range of pharmaceuticals primarily based upon the company s three key drug delivery technologies. Access currently has one approved product MuGard for the management of oral mucositis. Two cancer drug candidates ProLindac and Thiarabine are in phase II studies.

We are especially impressed with the company s Cobalaminbased oral drug delivery system. Both oral insulin and human growth hormone have achieved unprecedented oral bioavailability in animal models. Current share price is undervalued. We encourage investors accumulate the company s shares. Our six to twelve-month price target is $8.

ABEO